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Review
Bacteriophages Could Be a Potential Game Changer
in the Trajectory of Coronavirus Disease (COVID-19)
Marcin W. Wojewodzic, PhD1,2
Abstract
The pandemic of the coronavirus disease (Covid-19) has caused the death of at least 270,000 people as of the 8th of
May 2020. This work stresses the potential role of bacteriophages to decrease the mortality rate of patients infected by
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The indirect cause of mortality in Covid-
19 is miscommunication between the innate and adaptive immune systems, resulting in a failure to produce effective
antibodies against the virus on time. Although further research is urgently needed, secondary bacterial infections in
the respiratory system could potentially contribute to the high mortality rate observed among the elderly due to Covid-
19. If bacterial growth, together with delayed production of antibodies, is a significant contributing factor to Covid-
19’s mortality rate, then the additional time needed for the human body’s adaptive immune system to produce specific
antibodies could be gained by reducing the bacterial growth rate in the respiratory system of a patient. Independently
of that, the administration of synthetic antibodies against SARS-CoV-2 viruses could potentially decrease the viral
load. The decrease of bacterial growth and the covalent binding of synthetic antibodies to viruses should further
diminish the production of inflammatory fluids in the lungs of patients (the indirect cause of death). Although the first
goal could potentially be achieved by antibiotics, I argue that other methods may be more effective or could be used
together with antibiotics to decrease the growth rate of bacteria, and that respective clinical trials should be launched.
Both goals can be achieved by bacteriophages. The bacterial growth rate could potentially be reduced by the
aerosol application of natural bacteriophages that prey on the main species of bacteria known to cause respiratory
failure and should be harmless to a patient. Independently of that, synthetically changed bacteriophages could be
used to quickly manufacture specific antibodies against SARS-CoV-2. This can be done via a Nobel Prize awarded
technique called ‘‘phage display.’’ If it works, the patient is given extra time to produce their own specific
antibodies against the SARS-CoV-2 virus and stop the damage caused by an excessive immunological reaction.
Keywords: bacteriophages, bacterial infections, covid-19, phage display therapies
The Virus That Caused the Pandemic
The coronavirus pandemic has caused the death ofmore than 270,000 people, as reported by 8th May 2020
by the World Health Organization (WHO). The crisis we
observe is the joint effect of globalization and the properties of
the new virus (SARS-CoV-2), which causes the disease,
Covid-19. SARS-CoV-2 stands for ‘‘Severe Acute Respiratory
Syndrome COronaVirus 2’’ describing one of the most dan-
gerous symptoms in Covid-19. Although there have been past
warnings of the threat that respiratory targeting viruses pose,1
the SARS-CoV-2 virus has spread at an unprecedented rate
and it is devastating our health and economy globally. We
urgently need multiple approaches to tackle this crisis.
This short communication attempts to highlight the po-
tential for the use of natural bacteriophages to decrease the
mortality rate among patients infected by the SARS-CoV-2
virus. Covid-19 patients can develop SARS, leading to
atypical pneumonia2 that is mediated by cytokine storms.3
Possible Significance of Bacteria in Symptoms
for Covid-19
The most probable entrance road of the SARS-CoV-2 to
humans is the respiratory system, where the virus can disrupt
its equilibrium.
The indirect cause of death in Covid-19 patients could
be miscommunication between the innate and adaptive
1Cancer Registry of Norway (Kreftregisteret), Institute of Population-Based Cancer Research, Etiology Group, NO-0304, Oslo, Norway.
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immunological systems.4 The adaptive immune response
takes much longer than the innate immune response to begin
effectively attacking a new pathogen. This means there is a
period when only the innate immune system is fighting the
infection and, in this period, the innate immune system’s
response can become too aggressive when faced with a high
virus load, causing it to damage other systems. The growth of
the virus causes the innate immune system to secrete in-
flammatory material (fluid and inflammatory cells) into the
lungs. As a result, the lungs become filled with fluid reducing
the body’s ability to exchange gases.4
The debris of dying and virally infected human respiratory
cells can become a substrate for bacteria growth, a side effect
of the virus infection. This growth of bacteria then causes the
innate immune system to secrete additional inflammatory
material in nearby alveoli. Bacterial infections seem to pro-
voke a further reaction of the innate immune system, and they
may interact with virus infections.5 This process accelerates
as the virus continues to attack lung cells, and it thus creates
more cell debris substrate for the bacteria to feed on. This can
result in the innate immune system adding too much in-
flammatory fluid to the lungs, inhibiting gas exchange and
resulting in an urgent need for ventilation, and it can cause
sepsis and death.
The delay (or failure) of the production of antibodies
specific to the virus could explain why SARS-CoV-2 is so
dangerous for the elderly. A recent detailed review on im-
munity in Covid-19 summarizes state-of-the-art knowledge
of the host’s immunological response to the virus, and it
points out clear differences in disease progression between
younger and older patients.4
Immunosenescence (impairment of immune functions)
can delay the production of antibodies and is usually ex-
pected in elderly patients (Fig. 1B),6,7 which might be a part
of the cause for the high age-dependent mortality observed in
Covid-19 patients (Fig. 1A, B). Although data for Covid-19
are still scarce, there is evidence that having previously
contracted influenza predisposes the host to acquiring pneu-
mococcal colonization8,9 and therefore there is a known
mechanism for viral infections to cause bacterial colonization
in the human respiratory system. Further, the co-occurrence
of viruses and bacteria is well documented for other viruses.10
Although ecologists call this process a ‘‘succession,’’
medical doctors use the term ‘‘secondary infections.’’ For
instance Staphylococcus aureus, Staphylococcus pneumoniae
(pneumococcus), Aerococcus viridans, Haemophilius influ-
enza, and Moraxella catarrhalis are bacteria typically found
in influenza patients, as well as other respiratory commensals,
which occasionally turn into pathogens causing infection.11
A recent review suggests that bacterial infections, in-
cluding Acinetobacter baumanii and Klebsiella pneumoniae,
have been documented in Covid-19 patients, especially in the
intensive care unit setting.2 Non-survivors were more likely
to have sepsis and secondary infection, although detailed
bacteriology results were not reported. Secondary infections
were also positively correlated with steroid administration.2
At least part of the high mortality rate attributed to Covid-
19 could be due to bacterial infection of the respiratory sys-
tem,12,13 although we still do not have an accurate estimate
for the numbers. There might also be problems in producing
reliable estimates for these numbers due to the overwhelming
number of patients seen in clinics and the criteria for which
patients are admitted to bacteriology tests, and at what point
in the process. A recent report from Wuhan shows that at least
50% of patients dying developed secondary infections.12 The
median time given for these secondary infections to develop
is 17 days, although the range in time is quite large. It is
plausible that bacterial infections begin to colonize before
acute respiratory distress syndrome is developed.
In viral scenarios such as influenza, bacteria such as
Pseudomonas aeruginosa are known to spread rapidly.14,15 In
addition, the rapid and enormous response of the first-line,
innate immunity system causes general inflammation that can
change pulmonary structures (causing fibrosis), further re-
ducing oxygen uptake and causing permanent damage to the
respiratory tissue. This reaction can lead to the innate im-
munity system itself being the actual cause of death; how-
ever, the extent to which this reaction is caused by the body’s
response to the SARS-CoV-2 virus or to which it is caused by
its response to infection by bacteria (such as P. aeruginosa) is
not yet known and I postulate may differ over the course of
the infection.
The interplay between the time taken for the human body to
develop antiviral antibodies and the role of bacteria in the death
of older individuals is also not yet well known for Covid-19.
Integrative Approach Proposal
If bacterial growth, together with the delayed production of
antibodies, is a significant contributing factor to Covid-19’s
mortality rate, then the additional time needed for the human
body’s adaptive immunity system to produce antibodies
could be gained by reducing the bacterial growth rate in the
respiratory system of the patient. If the growth of bacteria in
lungs can be stopped, then the rate of liquid increase within
the lungs should also decrease. However, as the growth of the
virus is exponential, it might be necessary to decrease the
viral load at the same time as the bacterial load to slow down
the immunological response.
Natural Bacteriophages’ Potential—A Direct
Weapon Against Bacteria
Bacteriophages are viruses that selectively attack specific
species of bacteria and are otherwise harmless to animal cells,
including humans. They were discovered 100 years ago by
Frederick W. Twort and Félix d’Hérelle16 and are distributed
throughout Earth’s ecosystems17 and over a broad bacterial
host range, including bacteria naturally found in humans.18
It has been shown that the attack of bacteriophages is
specific, meaning that one species of bacteriophage targets
only a single species of bacteria (or even a specific strain of
one species).19 This specificity also points toward the ‘‘Red
Queen’’ co-evolutionary process between these two play-
ers.20,21 The scenario of the attack is as follows: (1) The
bacteriophage attaches itself to a susceptible bacterium, ex-
clusively infects the host bacterial cell and (2) hijacks the
bacterium’s biochemical machinery to produce multiple
copies of itself. (3) The bacterium then undergoes destruction
(lysis) and new copies of the bacteriophage are released and
infect, exclusively, other bacteria of the same species in the
neighboring areas.
Despite this known interplay between bacteriophages and
bacteria, research into bacteriophages and their potential
medical applications was largely abandoned for many years
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due to ‘‘The Antibiotics Revolution.’’ Antibiotics were
adopted as the main way of treating bacterial infections due
primarily to the fact that they are general purpose, as opposed
to bacteriophages that specifically target a single species of
bacteria. Other advantages include the fact that antibiotics are
usually fast acting, efficient, and relatively cheap to manu-
facture. However, there are several drawbacks as well to the
use of antibiotics. One of these is that, unlike bacteriophages,
antibiotics can destroy beneficial bacteria in addition to
harmful ones.22 More importantly, the overuse of antibiotics
can cause bacteria to evolve resistances to them, resulting in
antibiotic-immune ‘‘superbugs.’’23,24
In the current Covid-19 pandemic, around 70% of hospi-
talized COVID-19 patients worldwide receive antibiotics as
part of their treatment.25 This raises the danger of the emer-
gence of antibiotic-resistant strains of bacteria even higher
and creates an even greater need for the development of
alternative strategies to fight bacterial infections. Unlike
antibiotics, bacteriophage treatments would be far less sus-
ceptible to the development of resistances, as the bacterio-
phage itself can also adapt to overcome any resistance that the
bacteria develop.26
It has also been suggested that the presence of bacterio-
phages can have positive effects on human health and patient
recovery, suggesting that bacteriophages are to some extent
responsible for homeostasis of the microbiota.27 For instance,
a group investigating alternative treatments for Clostridium
difficile, a bacteria that can infect the bowel and cause diarrhea,
has identified a large set of bacteriophages that are effective at
killing this pathogen.28 This method is now being transformed
into a therapeutic treatment. We can find more examples of
how bacteriophages are being used for human or animal
models, in addition to different bioengineering methods using
bacteriophages that are currently being developed.29–31
Bacteriophages Used for Accelerated Therapeutic
Antibody Production Against the Virus
Despite the fact that bacteriophages’ potential to fight
bacterial infections has only recently been rediscovered, they
were successfully used as tools at the molecular level, leading
to Nobel Prize awards.32
Using a technique called phage display, bacteriophages have
the potential to quickly produce recombinant antibodies.33 This
technique of producing antibodies was developed for MERS-
CoV and successfully applied.34 In phage display, techniques
blocking ACE2 interaction could be engineered from the serum
of immune patients. The Yin-Yang biopanning method high-
lights the possibility of utilizing crude antigens for the isola-
tion of monoclonal antibodies by phage display. Before this,
FIG. 1. Theoretical time courses of the SARS-CoV-2 virus growth (red curves), bacterial growth (purple curves), and host
antibody production (blue curves) for four scenarios. (A) A young healthy individual who has no problems developing
antibodies to the virus infection. (B) An old individual who experiences delayed antibody production, resulting in bacterial
growth as well as increased virus growth. (C) An old individual for whom a bacteriophage cocktail against bacterial growth
was introduced as a part of standard therapy. Increase of bacteriophages is marked (green curve) with the time of treatment
(green arrow). The relationship between bacteriophages and bacteria can be described by the Lotkka-Voltera population
model. The viral load does not decrease until the body’s natural antiviral antibodies are produced but more time is bought
for this to happen. (D) An old individual for whom synthetic antibodies were introduced (brown curve), creating an
immediate reduction in the viral load and once again buying time for the natural antibodies to be produced. SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.
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artificial antibody production was primarily done by using
animals; however, this is both slower and less cost effective
than using bacteriophage display techniques.35 Another
benefit of this method is that monoclonal antibodies produced
by bacteriophage display techniques can be humanized.36
The use of antibody therapy for the control of viral diseases
has already been reviewed and some therapies have been
approved for human testing.37 As an example, the company
ProteoGenix launched accelerated therapeutic antibody
discovery by screening a naive antibody human library
(LiAb-SFMAX, scFv, Fab, IgG) or an immune human
antibody library (obtained from the plasma of COVID-19
survivors) by using the phage display technique (https://
bit.ly/2LlOsVQ). This demonstrates that accelerated thera-
peutic antibody discovery is highly feasible.
Therefore, there are two main ways that bacteriophages
could be used to decrease the mortality rate of the Covid-19
pandemic. They can be used to decrease the population of
bacteria in a patient’s respiratory system and/or bacterio-
phage display techniques can be used to efficiently manu-
facture synthetic antibodies against SARS-CoV-2 (Fig. 1D).
I propose a series of clinical trials for the use of cocktails of
bacteriophages (that target the main species of bacteria
known to cause respiratory problems) in treating Covid-19
patients and/or the use of phage display techniques to create
synthetic antibodies that target SARS-CoV-2 in the early
stages of infection.
Further Considerations for Bacteriophage
Therapy—Bacteriophages as Killers
The bacterial growth rate could potentially be reduced by
the aerosol application of bacteriophages that prey on the
main species of bacteria known to cause respiratory failures
(Fig. 1C). This can occur in a self-regulatory manner, similar
to ecological prey–predator regulation. The exponential
growth of the bacteriophage population (limited primarily by
the population of the bacteria it preys on) should allow for a
fast clearance, especially in cases where the bacterial popu-
lation has already grown significantly. The relationship can
be described by Lotka-Volterra or Kill-the-Winner popula-
tion model.38–40
In fact, we can already find evidence in literature that
pneumonia could be cured by nebulized bacteriophages.41
Prophylactically administered bacteriophages reduced lung
bacterial burdens and improved survival of antibiotic-
resistant S. aureus infected animals in the context of
ventilator-associated pneumonia. If needed, a selection of
bacteriophages and optimal target bacteria could be quickly
identified by a group of experts as the species of bacteria that
commonly cause respiratory problems are well known and a
bacteriophage that preys on a specific species can be quickly
identified by screening methods.42 If needed, quantitative
microbiome sequencing could potentially be used.43
There are assumptions that need to be met during the
clinical trials for the approach to work. (1) The cohort has to
be chosen to have a high probability of developing bacterial
infections. (2) It should be ensured to have the correct choice
of bacteriophages that both target the optimal bacteria can-
didates and are most effective at reducing that bacteria’s
population growth. (3) The bacteriophages should not inter-
fere with the patient’s innate or adaptive immune system. (4)
The patient does not have antibodies toward bacteriophages
used, nor develops any antibodies toward bacteriophages to
clear off the bacteriophage earlier than to SARS-CoV-2. We
know from bacteriophage therapy in the pneumonia system
that the rapid lysis of bacteria by bacteriophages in vivo does
not increase the innate inflammatory response compared with
antibiotic treatment.44 This is a promising finding and there
seemed to be positive effects on the patient’s immune sys-
tem.45 (5) Another obstacle could be a risk of a species of
bacteria developing resistance to the bacteriophage, accord-
ing to the co-evolutionary process mentioned. However, this
would be much less serious than the antibiotic resistance
problem as it would only reduce the effectiveness of that one
bacteriophage and there is the possibility of the bacterio-
phage also adapting to overcome any resistance to it. (6)
Finally, bacteriophages are so specific to one species of
bacteria, and there is very little chance of the bacteriophage
damaging any beneficial bacteria, but this should still be
verified in clinical trials. It has to be noted that the point here
is to decrease bacterial growth in critical time and therefore
allow the patient more time to recover from the Covid-19
infection.
Decreasing the Population Growth Rate of Bacteria
The response to antibiotics may be slower or smaller than
expected. This may be due to both antibiotic-resistant strains
and slow diffusion rate of the antibiotics in that area due to
bacterial biofilm formation.46 Also, in some cases, the pen-
etration of antibiotics into target tissues is also dependent on
the tissue type that was shown for lungs in tuberculosis sce-
narios.47 It has been shown that the sites of mycobacterial
infection in the lungs of patients have complex structures and
poor vascularization, which obstructs drug distribution to
these hard-to-reach and hard-to-treat disease sites, further
leading to suboptimal drug concentrations. Because of this,
there is the potential for the use of bacteriophages (entering
patients’ respiratory systems in a different way and acting
differently to antibiotics) to decrease the mortality rate of
patients infected by the SARS-CoV-2 virus.
Intensive use of antibiotics targeting Covid-19 in clinics
can further lead to bacterial resistance spreading in the hos-
pitals. Using bacteriophages could take pressure off this
problem. This could also shed light on the use of bacterio-
phages to decrease this problem in post–Covid-19 scenarios.
Decrease the Viral Load by Using Synthetic
Antiviral Antibodies
There are also assumptions that need to be met during the
clinical trials for the second approach to work. (1) The cohort
has to be chosen to have a bad prognosis (age >80) and high
viral load; (2) ensuring the correct choice of antibody that
targets the virus epitope and nothing else in the human body;
(3) the antibody should not cause failure of the immune
system (anaphylactic shock); (4) the dose and frequency
should be mathematically modeled; and (5) the delivery
system should be efficient.
Gaps in Knowledge
Before choosing the candidate bacteriophages, careful
literature studies will need to be done to check for potential
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known interactions. For example, it has been shown that
some bacteria can produce a biofilm when exposed to their
relevant bacteriophages,48 which could be an obstacle for the
development of these methods as a treatment for Covid-19
patients. Although most bacteriophages kill their bacterial
hosts, others can live inside the microbes without killing
them.49 Also, lessons from recent studies need to be carefully
followed. For instance, complex immune dysregulation in
Covid-19 patients with severe respiratory failure has been
observed.50
During the writing of this communication, the first im-
munological reviews were published, in which the authors
identified major gaps in knowledge that need to be addressed
by the scientific community.4 It is unknown how this may
complicate any treatment and further investigation is needed.
High Gain Approach
However, if a treatment using bacteriophages therapy can
be developed it is likely to prove practical as they can be
produced both quickly and cheaply. Production of antibodies
from the phage display techniques will have some costs of
production but, owing to recent progress, the development
should be simple. Bacteriophages can also be stored and
transported easily. I believe that bacteriophages have the
potential to be a practical tool in mitigating the SARS-CoV-2
pandemic, especially in patients with secondary bacterial
infection and high viral load. I believe that it is unlikely to
have any significant side effects, and that it has the potential
to save a great number of lives. The beauty of nature is that
although it can kill us, it can also come to our rescue.
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